How were Inspyr Therapeutics' earnings last quarter?

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) posted its quarterly earnings results on Monday, August, 14th. The company reported ($26.25) earnings per share for the quarter.

When did Inspyr Therapeutics' stock split?

Inspyr Therapeutics shares reverse split on Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Inspyr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inspyr Therapeutics investors own include Hon Hai Precision Industry (HNHPF) , iBio (IBIO) , Knight-Swift Transportation (KNX) , Danaher (DHR) , Co-Diagnostics (CODX) , Cleveland BioLabs (CBLI) , Cloudcall Group (CALL) , Blink Charging (BLNK) and BIO-key International (BKYI) .

How do I buy shares of Inspyr Therapeutics?

Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:NSPX

Inspyr Therapeutics (NSPX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free NSPX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 29.64 million shs
Average Volume: 13.19 million shs
Market Capitalization: $1.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Inspyr Therapeutics alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Inspyr Therapeutics

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

NSPX Stock News Headlines

April 4, 2024 | seekingalpha.com

EWTX Edgewise Therapeutics, Inc.

March 4, 2023 | benzinga.com

TG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, Predictions

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

October 12, 2021 | ca.finance.yahoo.com

Inspyr Therapeutics Announces New Holding Company Structure and Reverse Stock Split

See More Headlines

Receive NSPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2017
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:NSPX
CUSIP: N/A
CIK: 1421204
Web: www.genspera.com
Phone: (818) 597-7552
Fax: N/A
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,300,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -1,354.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.09
Quick Ratio: 0.09

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.07) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 543,152,000
Free Float: N/A
Market Cap: $1.47 million
Optionable: Not Optionable
Beta: -17.33

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Silvestre Raul
President, Chief Executive Officer & Director
Michael Elliott
Vice President-Clinical Operations

Key Competitors

View All Competitors

NSPX Stock Analysis - Frequently Asked Questions

How were Inspyr Therapeutics' earnings last quarter?: Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) posted its quarterly earnings results on Monday, August, 14th. The company reported ($26.25) earnings per share for the quarter.
When did Inspyr Therapeutics' stock split?: Inspyr Therapeutics shares reverse split on Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
What other stocks do shareholders of Inspyr Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inspyr Therapeutics investors own include Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Danaher (DHR), Co-Diagnostics (CODX), Cleveland BioLabs (CBLI), Cloudcall Group (CALL), Blink Charging (BLNK) and BIO-key International (BKYI).
How do I buy shares of Inspyr Therapeutics?: Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NSPX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial